Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13 | $12 | $9 | $11 |
| % Growth | 3.4% | 42.7% | -18.7% | – |
| Cost of Goods Sold | $2 | $3 | $1 | $1 |
| Gross Profit | $11 | $9 | $8 | $9 |
| % Margin | 87% | 76.2% | 87.6% | 88.3% |
| R&D Expenses | $87 | $91 | $73 | $83 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $41 | $46 | $42 | $52 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $128 | $137 | $114 | $135 |
| Operating Income | -$117 | -$127 | -$107 | -$125 |
| % Margin | -907.4% | -1,020.1% | -1,222% | -1,165.3% |
| Other Income/Exp. Net | $13 | $15 | $17 | $20 |
| Pre-Tax Income | -$103 | -$112 | -$89 | -$105 |
| Tax Expense | $0 | $0 | $0 | -$9 |
| Net Income | -$103 | -$112 | -$89 | -$97 |
| % Margin | -803.1% | -899.4% | -1,023.3% | -899.6% |
| EPS | -1.78 | -1.93 | -1.55 | -1.69 |
| % Growth | 7.8% | -24.5% | 8.3% | – |
| EPS Diluted | -1.78 | -1.93 | -1.55 | -1.69 |
| Weighted Avg Shares Out | 58 | 58 | 57 | 57 |
| Weighted Avg Shares Out Dil | 58 | 58 | 57 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $15 | $16 | $18 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$102 | -$111 | -$105 | -$124 |
| % Margin | -792.4% | -889.3% | -1,207.3% | -1,152.6% |